IGHE and asthma: Currently, it is the only anti-IgE agent available for use in asthma approved in the US for use in patients who display all of the following characteristics: at least six years of age, have a diagnosis of moderate to severe persistent asthma, achieve inadequate control of asthma symptoms despite the use of medium- or high-dose inhaled glucocorticoids, have a serum IgE level between 30 and 700 international units per milliliter (IU/mL), and are sensitive (as demonstrated by a positive skin test) to specific allergens year-round [14].